Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TC-WYRE: TAXUS Express Stent vs. Cypher Stent - What's Your Real Life Experience?

This study has been completed.
Information provided by:
Boston Scientific Corporation Identifier:
First received: June 23, 2006
Last updated: October 7, 2008
Last verified: October 2008
To compare the relative efficacy and safety of the TAXUS Express2 stents and the Cypher stents among a broad, unselected patient population treated in a nationwide, multi-center clinical registry representative of 'real-world,' contemporary clinical practice. A secondary objective is to examine performance of the two stents in pre-specified subgroup populations and examine regional and national patterns in outcomes.

Condition Intervention
Coronary Artery Disease
Device: TAXUS Stent and Cypher Stent

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: TC-WYRE: TAXUS Express Stent vs. Cypher Stent - What's Your Real Life Experience?

Further study details as provided by Boston Scientific Corporation:

Estimated Enrollment: 2500
Study Start Date: May 2006
Estimated Study Completion Date: June 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients treated with a TAXUS Express2 stent or a Cypher stent between April 1, 2005 and June 30, 2005.

Exclusion Criteria:

  • Simultaneous treatment with both TAXUS and Cypher stents during the index revascularization. Patients who have undergone previous target vessel(s), stenting procedure within 9 months of the index procedure will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00344630

United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Boston Scientific Corporation
Principal Investigator: William O'Neill, MD Duke University
  More Information Identifier: NCT00344630     History of Changes
Other Study ID Numbers: S5572  BSC 
Study First Received: June 23, 2006
Last Updated: October 7, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases processed this record on October 25, 2016